MedTrace Logo

MDD POC Study GSK372475 Subjects Depressive Disease

NCT00420641 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 492

Last updated 2018-02-05

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.

Conditions

  • Depressive Disorder

Interventions

DRUG

GSK372475

GSK372475 1.0-1.5 mg/day

DRUG

Paroxetine

Paroxetine 20-30 mg/day

OTHER

Placebo

Placebo to Match

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-19
Primary Completion
2008-06-01
Completion
2008-10-15

Countries

  • Bulgaria
  • Canada
  • Chile
  • Costa Rica
  • Croatia
  • France
  • Germany
  • India
  • Italy
  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420641 on ClinicalTrials.gov